Marwyn Acquisition Company Iii Limited (MAC3) News

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday...

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC...

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Builds on U.S. biosimilar portfolio of seven products with three commercial and four in pipeline 8th biosimilar expands portfolio into allergy...

Amneal Releases 2023 Environmental, Social and Governance Report

Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a...

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

The Company’s leading R&D capabilities and robust, expanded manufacturing capacity are helping to address chronic market shortages Amneal...

Amneal to Participate at Upcoming Investor Conference

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report